Should glucocorticoids be withheld in a COVID-19 patient with renal and hepatic dysfunction?

Should Steroids Be Withheld in COVID-19 Patients with Renal and Hepatic Dysfunction?

No, do not withhold steroids in COVID-19 patients with renal and hepatic dysfunction if they require supplemental oxygen—dexamethasone 6 mg daily should be administered because the mortality benefit (20-35% relative reduction) outweighs theoretical concerns about organ dysfunction, and steroids can be used when potential benefits are greater than risks even in patients with liver disease. 1, 2

Evidence-Based Treatment Algorithm

Step 1: Assess Oxygen Requirement

Patients requiring ANY supplemental oxygen (low-flow, high-flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation):

• Administer dexamethasone 6 mg once daily (oral or IV) for up to 10 days 1, 2, 3
• This reduces 28-day mortality from 25% to 21.5% in oxygen-requiring patients (20% relative reduction) 2, 3
• In mechanically ventilated patients, mortality drops from 40.7% to 29.0% (35% relative reduction) 1, 2

Patients NOT requiring oxygen (SpO₂ ≥92% on room air):

• Do NOT give dexamethasone—mortality increases from 13.2% to 17.8% 2, 3, 4
• This represents clear harm with a relative risk of 1.22 3

Step 2: Specific Considerations for Hepatic Dysfunction

In COVID-19 patients with liver disease, steroids should NOT be withheld:

• Steroids or immunosuppressants can be used when potential benefits are greater than the risk 1
• Maintain sufficient steroid dose to avoid adrenal insufficiency or aggravation of underlying liver disease 1
• Consider minimizing the dosage of high-dose steroids, but do not discontinue if needed for disease control 1
• Monitor liver function tests during treatment, particularly if using anakinra concurrently 1

Step 3: Specific Considerations for Renal Dysfunction

Renal dysfunction is NOT a contraindication to dexamethasone:

• The standard 6 mg daily dose does not require adjustment for renal impairment 2, 3
• COVID-19 itself can cause FSGS and acute kidney injury; glucocorticoids have shown efficacy in treating COVID-19-associated glomerulonephritis 5
• One case report demonstrated partial remission of COVID-19-related FSGS with high-dose glucocorticoid therapy 5

Step 4: Dosing Specifications

Standard regimen:

• Dexamethasone 6 mg once daily (oral or IV equivalent) for up to 10 days or until discharge 1, 2, 3
• This dosing is derived from the RECOVERY trial (6,425 patients, 176 hospitals) 2, 3

Alternative if dexamethasone unavailable:

• Methylprednisolone 1-2 mg/kg/day for 3-5 days in severe/critical patients 1, 2, 3
• This reflects a class effect of corticosteroids 2

Do NOT use higher doses:

• Dexamethasone 20 mg daily followed by 10 mg daily significantly increased mortality (19% vs 12%, rate ratio 1.59) in patients on simple oxygen 4
• Higher doses also increased non-COVID pneumonia (10% vs 6%) and hyperglycemia requiring insulin (22% vs 14%) 4

Critical Monitoring Parameters

Metabolic monitoring:

• Check blood glucose regularly to detect corticosteroid-induced hyperglycemia 2, 3
• Monitor serum potassium to identify hypokalemia 3

Hepatic monitoring:

• Monitor liver enzymes if patient has pre-existing liver disease 1
• Watch for signs of hepatic decompensation 1

Renal monitoring:

• Track serum creatinine and urine output 5
• Monitor for proteinuria if glomerular involvement suspected 5

Combination Therapy Considerations

If patient deteriorates despite dexamethasone or within first 24 hours of ventilatory support:

• Consider adding IL-6 receptor antagonist (tocilizumab or sarilumab) 1, 2, 3
• Patients receiving IL-6 antagonists should already be on or should receive corticosteroids unless contraindicated 1, 2

Common Pitfalls to Avoid

Do not extrapolate concerns from other conditions:

• The mortality benefit of dexamethasone in oxygen-requiring COVID-19 patients is established with moderate-to-high quality evidence 1, 2, 3
• Theoretical concerns about steroid use in liver or kidney disease are outweighed by proven mortality reduction 1

Do not delay steroids due to organ dysfunction:

• In patients with autoimmune liver disease or post-transplant rejection, rapid reduction or discontinuation of steroids can exacerbate disease 1
• Maintain sufficient dose to avoid adrenal insufficiency 1

Do not give steroids to non-hypoxic patients:

• This is the single most important contraindication—mortality increases in patients not requiring oxygen 2, 3, 4

Do not use excessive doses:

• Higher doses (20 mg then 10 mg daily) increase mortality compared to standard 6 mg daily 4

Evidence Quality Summary

The recommendation to use dexamethasone 6 mg daily in oxygen-requiring COVID-19 patients is based on:

• The RECOVERY trial (6,425 patients, moderate-to-high quality evidence) 2, 3
• European Respiratory Society strong recommendation 1, 2, 3
• EULAR 2022 guidelines supporting glucocorticoid use in hospitalized patients requiring oxygen 1

The guidance that hepatic and renal dysfunction should not preclude steroid use comes from:

• Clinical and Molecular Hepatology 2020 guidelines on managing liver disease during COVID-19 1
• Case evidence of successful glucocorticoid treatment in COVID-19 patients with renal complications 5